BioNTech SE(BNTX) 종목 분석 — 적정가치·리스크·해자 평가
NMS · Healthcare · Biotechnology
BioNTech SE는 지금 안전한 투자처인가?
BioNTech SE's Altman Z-Score of 7.84 places it in the safe zone. Fair value estimate is not available for this stock. Moat rating: 2.3/5 stars.
BioNTech SE는 파산할 가능성이 있는가? Altman Z-Score 분석
Z-Score of 7.84 is above 3.0, indicating the company is financially healthy by this metric.
- 1.8 미만 — 위험 구간(파산 리스크 높음)
- 1.8~3.0 — 회색 구간(불확실성 높음)
- 3.0 초과 — 안전 구간(재무 건전)
BNTX의 Z-Score를 구성하는 요인은?
| 구성 요소 | 산식 | 수치 | 가중치 | 기여도 |
|---|---|---|---|---|
| A · Working Capital / Total Assets | WC / TA | 0.6369 | 1.2 | 0.76 |
| B · Retained Earnings / Total Assets | RE / TA | 0.8169 | 1.4 | 1.14 |
| C · EBIT / Total Assets | EBIT / TA | -0.0471 | 3.3 | -0.16 |
| D · Market Cap / Total Liabilities | MCap / TL | 9.9346 | 0.6 | 5.96 |
| E · Revenue / Total Assets | Rev / TA | 0.1305 | 1.0 | 0.13 |
BNTX의 재무 건전성은 어떻게 변화해 왔는가?
| 연도 | Z-Score | 구간 |
|---|---|---|
| 2022 | 9.81 | 안전 |
| 2023 | 8.42 | 안전 |
| 2024 | 7.36 | 안전 |
| 2025 | 7.84 | 안전 |
출처: BNTX의 SEC EDGAR 최신 10-K 기반 산출.
BioNTech SE의 진정한 가치는 얼마인가?
출처: 실적 데이터는 SEC EDGAR 제출 서류, 시장 데이터는 Yahoo Finance. 최근 분기가 반영되지 않았을 수 있습니다.
BioNTech SE는 지속적인 경쟁우위를 보유하고 있는가?
Moat rating: 2.3/5.
BNTX의 해자 점수를 구성하는 요인은?
ROIC Stability
ROIC variability over the past decade. Score: 2/5.
Gross Margin Trend
Gross margin trajectory over the past decade. Score: 2/5.
Switching Costs
Estimated customer lock-in based on margin level. Score: 3/5.
BNTX의 투하자본수익률은 얼마나 안정적인가?
| 연도 | ROIC | 트렌드 |
|---|---|---|
| 2022 | 60.0% | — |
| 2023 | 5.8% | Declining |
| 2024 | -3.4% | Declining |
| 2025 | -5.3% | Declining |
출처: ROIC는 SEC EDGAR 제출 서류 기반 산출.
BioNTech SE의 배당은 안전한가?
BioNTech SE의 주요 재무 지표
| 지표 | 최신 | 1년 전 | 3년 전 | 트렌드 |
|---|---|---|---|---|
| Revenue | $2.9B | $2.8B | $17.3B | Declining |
| Net Income | −$1.1B | −$0.7B | $9.4B | Declining |
| Free Cash Flow | −$0.3B | −$0.2B | $13.2B | Declining |
| Gross Margin | 77.6% | 80.3% | 82.7% | Declining |
BNTX의 분석에 영향을 미치는 최근 이벤트
BNTX 실적 발표 예정
실적 발표 예정. 컨센서스 EPS 예상치: $-1.91. 매출 예상치: $165.9M.
BNTX 애널리스트 컨센서스: 74% 강세 (14/19명)
1 강력 매수, 13 매수, 4 중립, 0 매도, 1 강력 매도. 컨센서스 목표가: $130.84 (20.5% 상승 여력).
BNTX EPS 예상치 30.4% 하회
실제 EPS: $-0.33 예상치 $-0.25.
BNTX EPS 예상치 220.3% 하회
실제 EPS: $-0.12 예상치 $0.10.
BNTX EPS 예상치 13.8% 하회
실제 EPS: $-1.60 예상치 $-1.41.
BNTX EPS 예상치 26.3% 상회
실제 EPS: $-1.73 예상치 $-2.35.
BNTX EPS 예상치 144.4% 상회
실제 EPS: $1.08 예상치 $0.44.
BioNTech SE에 대한 자주 묻는 질문
What is BioNTech SE stock price today?
BioNTech SE (BNTX) stock price is $108.60 as of the latest market close, traded on the NASDAQ exchange.
What does BioNTech SE do?
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. It offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer.
What is BioNTech SE market cap?
BioNTech SE has a market capitalization of $27.46B, classifying it as a large-cap stock in the Healthcare sector.
What sector and industry is BNTX in?
BioNTech SE operates in the Healthcare sector, specifically within the Biotechnology industry. It trades on the NASDAQ under the ticker symbol BNTX.
Is BNTX stock overvalued or undervalued?
We do not have sufficient earnings data to produce a reliable fair value estimate for BioNTech SE at this time. Stocks without stable earnings history are difficult to value using traditional models.
What is BNTX stock forecast and analyst target price?
Based on 18 Wall Street analysts, the consensus price target for BioNTech SE is $130.84, implying upside of 20.5% from the current price.
- Analyst High Target: $173.60
- Analyst Low Target: $75.42
Note: Analyst targets are shown for reference and are not used in our valuation model.
Is BioNTech SE revenue and earnings growing?
Here are the analyst consensus growth estimates for BioNTech SE:
- Revenue growth (current year est.): -23.1%
- EPS growth (current year est.): -763.0%
- Revenue growth (next year est.): 4.8%
- EPS growth (next year est.): 9.5%
What are BioNTech SE's key financial metrics?
| Metric | Latest | Trend |
|---|---|---|
| Revenue | $2.9B | Declining |
| Net Income | −$1.1B | Declining |
| Free Cash Flow | −$0.3B | Declining |
| Gross Margin | 77.6% | Declining |
What is BNTX's P/E ratio?
The price-to-earnings ratio measures how much investors pay per dollar of earnings:
- Forward P/E (next 12 months est.): -24.7x
How volatile is BNTX stock?
BioNTech SE has a beta of 1.59, meaning it is significantly more volatile than the broader market. A beta above 1.0 indicates higher price swings relative to the S&P 500, while below 1.0 suggests more stability.
How much cash and debt does BioNTech SE have?
BioNTech SE's balance sheet shows:
- Total Cash: $13.74B
- Total Debt: $267.4M
- Net Cash Position: $13.47B
A positive net cash position means the company holds more cash than debt, reducing financial risk.
What is BioNTech SE's free cash flow?
BioNTech SE generated $-1.10B in trailing twelve-month free cash flow (from $456.0M in operating cash flow). Free cash flow represents the cash available for dividends, buybacks, and debt reduction after all capital expenditures.
Does BioNTech SE pay a dividend?
BioNTech SE does not currently pay a regular dividend to shareholders. The company may be reinvesting all profits back into growth, or it may have suspended its dividend.
Is BioNTech SE at risk of going bankrupt?
BioNTech SE's Altman Z-Score is 7.84, placing it in the safe zone (above 3.0) — bankruptcy risk is low. The Z-Score uses five balance sheet ratios to predict bankruptcy probability within two years.
Does BioNTech SE have a durable competitive advantage?
BioNTech SE scores 2.3/5 stars (Weak moat) in our moat analysis:
- ROIC Stability: 2/5
- Gross Margin Trend: 2/5
- Switching Costs: 3/5
A score above 3.5 suggests meaningful pricing power and a defensible market position.
What is BNTX's return on equity (ROE)?
BioNTech SE's return on equity is -5.9%. ROE measures how efficiently a company generates profits from shareholder equity. An ROE above 15% is generally considered strong, while below 10% may signal inefficiency.
How do I buy BNTX stock?
BNTX shares can be purchased through any brokerage account that provides access to the NASDAQ. Common steps:
- Open an account with a broker (e.g., Fidelity, Schwab, Interactive Brokers)
- Search for ticker symbol BNTX
- Place a market or limit order for your desired number of shares
This is not investment advice. Always do your own research before buying any stock.
Is BNTX a value stock or speculative?
FairValueLabs classifies BioNTech SE as Pure Speculation. It lacks the financial stability or valuation margin typically required for value investing. This stock is considered high risk.
Who is the CEO of BioNTech SE?
The current CEO of BioNTech SE is Dr. Ugur Sahin M.D..
What is BNTX's earnings per share (EPS)?
Earnings per share measures the company's profit allocated to each outstanding share:
- Trailing EPS (last 12 months): $-5.54
- Forward EPS (next 12 months est.): $-4.40
- Analyst consensus EPS (this year): $-4.14
- Analyst consensus EPS (next year): $-3.75
FairValueLabs가 분석하는 기타 Healthcare 기업
FairValueLabs 면책 조항
본 페이지의 모든 밸류에이션, 점수, 평가, 분류는 FairValueLabs 독자 밸류에이션 시스템으로 산출된 것입니다. 실제 시장 가치, 수익 보장 또는 전문적인 투자 조언을 의미하지 않습니다. 교육 및 리서치 목적의 분석 추정치입니다.
This is not financial advice. All data is sourced from SEC EDGAR public filings. Always consult a qualified financial advisor before making investment decisions.
최종 업데이트: 2026년 4월 22일. 데이터 소스: SEC EDGAR(재무제표), Yahoo Finance(시장 데이터, 애널리스트 컨센서스). 최근 분기 데이터가 반영되지 않았을 수 있습니다.